<< Back To Search

A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

Notify the Multiple Myeloma Research Foundation you are interested in this trial
NCT05519085
Age 18 +
Sex Both
Phase Phase 3
Third Opinion Trial Synopsis
In this study, doctors want to see which treatment works better and is safer for people with multiple myeloma that has come back or hasn't responded to treatment. They will compare a new treatment called 480Vd to an older treatment called PVd. The participants have already received 1 to 3 treatments before and have tried lenalidomide before.
Third Opinion AI Generated Synopsis

Trial Summary
The purpose of this study is to compare the efficacy and safety of mezigdomide (CC-92480), bortezomib and dexamethasone (MeziVd) versus pomalidomide, bortezomib and dexamethasone (PVd) in participants with relapsed or refractory multiple myeloma (RRMM) who received between 1 to 3 prior lines of therapy and who have had prior lenalidomide exposure.
from ClinicalTrials.gov

Locations & Contact

Fill out the form and to let the Multiple Myeloma Research Foundation know you are interested in this trial.

Please share any additional considerations or concerns:
Example: Are you newly diagnosed? What treatments have you already been on?

Contacts: